FDA re­jects Intar­cia’s hot­ly pro­mot­ed di­a­betes drug/de­vice, cit­ing man­u­fac­tur­ing is­sues

Boston-based Intar­cia Ther­a­peu­tics be­came the lat­est ca­su­al­ty of the FDA’s man­u­fac­tur­ing stan­dards. The agency has re­ject­ed Intar­cia’s im­plant­ed di­a­betes drug/de­vice, which com­pa­ny ex­ecs have …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER